Lisa M. DeFrancesco | Intercept Pharmaceuticals, Inc. |
Mark E. Pruzanski | Intercept Pharmaceuticals, Inc. |
Jerome B. Durso | Intercept Pharmaceuticals, Inc. |
Sandip S. Kapadia | Intercept Pharmaceuticals, Inc. |
Michael J. Yee | Jefferies LLC |
Yasmeen Rahimi | Piper Sandler Companies |
Alethia Young | Cantor Fitzgerald Securities |
Joel L. Beatty | Citigroup Global Markets, Inc. |
Jay Olson | Oppenheimer & Co., Inc. |
Mayank Mamtani | B. Riley FBR, Inc. |
Brian Abrahams | RBC Capital Markets LLC |
Jim Birchenough | Wells Fargo Securities LLC |
Salveen Richter | Goldman Sachs & Co. LLC |
Alan Carr | Needham & Company, LLC |
Jack Allen | Robert W. Baird & Co., Inc. |
Aspen Mori | BofA Securities, Inc. |
Steven Seedhouse | Raymond James & Associates, Inc. |
Michael V. Morabito | Chardan Capital Markets, LLC |
Good day, ladies and gentlemen, and thank you for standing by. Welcome to the Second Quarter 2020 Intercept Pharmaceuticals Earnings Conference Call. At this time all participants are in a listen-only mode. After the speakers' remarks, there will be a question-and-answer session. At this time, I would now like to turn the conference over to Ms.